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Abstract
Background: Human renalase (RNLS), a recently identified flavoprotein with oxidoreductase activity, is secreted into
blood by kidneys and metabolizes circulating catecholamines. Recent studies have revealed that common
polymorphisms in RNLS gene might affect the risk of several cardiovascular conditions in hemodialyzed patients.
However, the exact mechanism underlying this link remains unclear. The study aims to investigate the association
between RNLS gene polymorphisms and plasma renalase level in ESKD patients undergoing hemodialysis (HD
group) and healthy controls (HC).
Methods: A total of 309 hemodialyzed patients and 90 controls were enrolled in the study. All the participants
were genotyped for two RNLS SNPs (rs2576178 and rs10887800) using PCR-RFLP method. Plasma renalase
concentrations were determined by enzyme-linked immunosorbent assay (USCN Life Science Inc., Wuhan, China).
The IBM SPSS Statistics for Windows, version 20 (IBM Corp., Armonk, NY, USA) was used for statistical analyses.
Results: Genotype distribution and allele frequencies of studied SNPs did not differ between two analyzed groups,
p > .050. RNLS concentration in HD group (33.54 μg/mL) was significantly higher than in HC (13.16 μg/mL), p < .001. HD
patients with rs10887800AA genotype had lower renalase level (29.32 μg/mL) compared to those with AG (34.52 μg/
mL), p < .010 and GG genotype (35.91 μg/mL), p < .010. No significant differences in plasma RNLS between
rs10887800AG and GG carriers were observed, p > .050. Interestingly, in HC group rs10887800 polymorphism did not
influence RNLS concentration. Rs2576178 SNP did not affect the level of plasma RNLS either in HD group or in HC.
Conclusion: Rs10887800 polymorphic variant of RNLS gene influences the level of circulating RNLS in patients undergoing
hemodialysis, and thus elucidates the potentially functional relevance of this polymorphism in HD population.
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Background
Human renalase (RNLS), a recently identified flavoprotein
with oxidoreductase activity, is secreted into blood mainly
by kidneys and metabolizes circulating catecholamines [1,
2]. By the regulation of the sympathetic tone, RNLS
modulates cardiac functions and systemic blood pressure
[3]. Experimental data indicate that, apart from its enzym-
atic activity, RNLS may also act as a cytokine and manifest
cytoprotective and immunomodulary properties [4, 5].
Seven isoforms of RNLS (hRenalase 1–7) have been
identified so far. hRenalase 1, a 342 amino acids protein
with a molecular weight of ~ 37.8 kDa, is the most highly
expressed form [6]. The renalase gene (RNLS) is posi-
tioned on chromosome 10 (10q23.31), has 13 exons and
several polymorphic variants [7]. The recent studies on
hemodialyzed population have revealed that single nucleo-
tide polymorphisms (SNPs) of RNLS gene affect the risk
of cardiovascular conditions such as arterial hypertension
(HY) or coronary artery disease (CAD) [8, 9]. However,
the exact mechanism underlying the functional interplay
between those pathologies and RNLS genetic variants
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remains unknown. To clarify the functional relevance of
RNLS polymorphisms we performed a study that aimed to
investigate whether two SNPs of the RNLS gene
(rs10887800 and rs2576178) influence plasma RNLS con-
centration in hemodialyzed patients and healthy controls.
Methods
A total of 399 participants, including 309 end-stage kidney
disease (ESKD) patients (HD group) and 90 healthy con-
trols (HC group) were consequtively enrolled in the study
from January 1, 2012 until December 31, 2013. There were
more females (53.64%) than males (46.36%). The mean age
of the study population was 59.25 ± 11.32 years. All subjects
were Caucasians of Polish origin. The most common cause
of ESKD was diabetic kidney disease (23%). The remaining
reasons were as follows: chronic glomerulonephritis
(18.2%), hypertensive kidney disease (12.6%), autosomal
dominant polycystic kidney disease (10%), chronic tubulo-
interstitial nephritis (9.1%), obstructive nephropathy (8.4%)
and others or undefined (18.7%). Patients with ESKD were
recruited from five hemodialysis (HD) units in eastern
Poland. All patients received standard bicarbonate
hemodialysis with low-flux synthetic membranes thrice-
weekly for 3–5 h per session. At the beginning of the
dialysis blood samples for renalase measurements and
genetic research were drawn from the venous side of the
vascular access into the EDTA (ethylenediaminetetraacetic
acid) containers. Socio-demographic and clinical data were
collected by nephrologists through interview, patient’s med-
ical records analysis and physical examination. Adequacy of
hemodialysis treatment in all HD patients was assessed by
the calculator, which uses the Daugirdas II equation
formula for Single Pool Kt/V for urea (spKt/Vurea).
Healthy controls group was obtained from volunteers
(hospital workers or blood donors) without history of
chronic diseases. According to the Declaration of
Helsinki all participants signed the informed consent
document. The study protocol was approved by the local
Ethics Committee.
The plasma renalase measurement
The blood samples were taken from all individuals into the
EDTA tubes. Plasma was separated and stored at −80 °C
until the assay. Renalase concentrations were determined by
commercially available enzyme-like immunosorbent assay
(ELISA) kits from USCN Life Science Inc. (Wuhan, China).
DNA isolation and genotyping
In the study two renalase gene polymorphisms (rs2576178
in 5′ flanking region and rs10887800 in intron 6) were
genotyped using PCR-RFLP (polymerase chain reaction-
restriction fragment length polymorphism) technique.
Genomic DNA was obtained from peripheral blood
leukocytes in accordance with the modified protocol of
Madisen et al. [10]. Primers sequences used for analysis were
as follows: rs10887800 SNP sence 5′-CAGGAAAGAAAA-
GAGTTGACAT-3′ antisense 5′-AAGTTGTTCCAGC-
TACTGT-3′ and rs2576178 SNP sense 5′-AGCAGAGA
AGCAGCTTAACCT-3′ antisense 5′-TTATCTGCAAGT-
CAGCGTAAC-3′. DNA amplification was carried out in a
PTC 200 Thermal Cycler (MJ Research, Inc. Waltham,
MA). All reagents were from MBI Fermentas (St. Leon-Rot,
Germany). The 30 μl of final volume contained: 300 ng
DNA, 1 μM of each primer, 200 μM each dNTP, 1.5 mM
MgCl2, 50 mM KCl, 10 mM Tris-HCl buffer (pH 8.3) and 2
U Taq polymerase. The reaction conditions were: initial
denaturation at 95 °C for 6 min followed by 35 cycles of
denaturation at 94 °C for 30s, annealing at 60 °C for 30s,
extension at 72 °C for 1 min and the final extension for
7 min. The 10 μl of PCR products were digested at 37 °C for
6–10 h with 5 U of Pst I and Msp I restriction endonucle-
ases, then separated by 2.5% agarose gel electrophoresis and
finally identified with ethidium bromide staining.
Statistical analysis
The IBM SPSS Statistics software package (version 20, IBM
Corp., Armonk, NY, USA) was applied for data analysis. A
two-tailed p-value < .050 was regarded as statistically signifi-
cant. Hardy-Weinberg equilibrium was tested using the
conventional χ2 goodness-of-fit test. The distribution of
genotype and the allele frequency were calculated by a 2 ×
2 contingency χ2 test. The means of continuous variables
were compared between two independent study groups by
a student’s t test, whereas discrete variables by a χ2 test of
independence.
Plasma renalase concentrations were compared between
three genotype-based subgroups by analysis of variance
(ANOVA). The Bonferroni test was used for post-hoc ana-
lyses. Subsequently, analysis of covariance (ANCOVA)
was conducted to assess the influence of genotypes on
RNLS level after adjustment for potentially confounding
effect of age, sex, BMI, albumin and hemoglobin level, the
presence of hypercholesterolemia and residual diuresis.
Sidak’s correction test was used for post-hoc analyses.
Results
All the participants were genotyped for two RNLS gene
polymorphisms: rs10887800 (intron 6) and rs2576178 (5′
flanking region) and their plasma RNLS concentrations
were measured. Demographic and clinical characteristics of
the study groups are summarized in Table 1. Compared
with controls HD patients were older (64.1 ± 14.1 years vs
42.4 ± 11.3 years, p < .001) and more frequently male
(50.8% vs 31.1%, p < .001). They also have higher mean
plasma RNLS level (33.54 ± 12.37 μg/mL vs 13.16 ± 4.5 μg/
mL p < .001). The genotypes distribution in all studied
groups was in Hardy-Weinberg equilibrium, p > .050. The
prevalence of genotypes and allele frequencies for both
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SNPs did not differ between HD patients and HC, p < .050.
As shown in Table 2 among HC group no genotype-based
differences in mean plasma RNLS levels were observed,
whereas such variations were noticed in HD population
(Table 3). HD patients with rs10887800AA genotype had
significantly lower RNLS level (29.32 ± 9.89 μg/mL) com-
pared to those with AG (34.52 ± 13.12 μg/mL), p < .010 and
GG genotype (35.91 ± 12.07 μg/mL), p < .010. Homozygotes
rs10887800GG and AG carriers did not differ in terms of
mean plasma RNLS concentrations, p > .050 (Fig. 1). In
contrast, rs2576178 SNP did not affect the level of plasma
renalase in this population. Moreover, in HD group the dif-
ferences in RNLS levels between genotypes didn’t change
statistically after adjustment for potentially confounding ef-
fect of age, sex, BMI, albumin and hemoglobin level, the
presence of hypercholesterolemia and residual diuresis.
Thus, mean plasma RNLS levels in HD patients with
rs2576178AA, AG and GG genotypes were: 33.33 ± .913,
33.59 ± 1.122, 35.26 ± 2.541 μg/mL, respectively, p > .050.
Whereas, mean plasma RNLS levels in HD patients with
rs10887800AA, AG and GG genotypes were: 28.77 ± 1.324,
34.32 ± .910, 37.12 ± 1.424 μg/mL, respectively, p < .010.
Discussion
In the present study, we observed for the first time that
rs10887800 polymorphism of the RNLS gene (located within
intron 6) influences plasma RNLS level in hemodialyzed
population. Interestingly, such effect was not observed in
healthy controls. HD patients with rs10887800AA genotype
had significantly lower RNLS concentration compared to
AG and GG carriers. Furthermore, rs10887800AG heterozy-
gotes manifested intermediate values of plasma RNLS,
therefore we have suspected a gene dose effect. Obtained re-
sults support the hypothesis that rs10887800 polymorphism
plays a functional role in RNLS gene regulation process.
However, it remains unclear whether this intronic SNP
exerts a direct impact on RNLS gene expression or whether
instead it is in linkage disequilibrium with another func-
tional SNP. Likewise, it is still unknown why the effect of
rs10887800 polymorphism on RNLS level varied across
different population groups. It could be modulated by
enviromental components associated with ESKD or
hemodialysis procedure (e.g., increased oxidative stress,
sympathetic hypractivity) but the role of other regulatory
mechanisms should be considered. Recent studies have
revealed that several transcription factors (viz. Sp1, STAT3
and ZBP 89) play a crucial role in the regulation of RNLS
gene transcription [11]. In addition, it was demonstrated
that nicotine, dopamine and epinephrine activate RNLS gene
expression in various cell types [12, 13]. Furthermore,
studies by Kalyani et al. provided an evidence for post-
transcriptional regulation of both mouse and human RNLS
genes by miR-29 and miR-146 microRNAs [14].
As far as the authors know no other papers concerning
the influence of RNLS gene variants on plasma RNLS con-
centrations have been published. Data from genome-wide
association studies (GWAS) have revealed the link between
rs10749571 polymorphism (3′ untranslated region of RNLS






Age (years) 64.1 ± 14.1 42.4 ± 11.3 <.001
Sex (Male/Female) 157/152 28/62 <.001
BMI (kg/m2) 25.8 ± 5.3 25.3 ± 4.0 >.050
spKt/Vurea 1.39 ± .62 NA
Plasma renalase (μg/mL) 33.54 ± 12.37 13.16 ± 4.5 <.001
Rs10887800
GG/AG/AA 71/161/77 16/49/25 >.050
G vs A .49/.51 .45/.55 >.050
Rs2576178
GG/AG/AA 23/118/168 7/33/50 >.050
G vs A .27/.73 .26/.74 >.050
Continuous variables are presented as means ± SD (standard deviation).
Discrete variables are presented as numbers. HD; hemodialyzed, BMI; Body
Mass Index, spKt/V; single-pool Kt/V for urea, NA; not applicable, *t-student or
χ2 tests
Table 2 Clinical characteristics of healthy controls classified according to the renalase gene polymorphisms
Variables POL Genotypes p value*
AA AG GG
Age (years) 1 42.52 ± 10.52 42.06 ± 13.21 43.13 ± 8.51 >.050
2 42.52 ± 11.54 42.18 ± 11.28 42.87 ± 11.82 >.050
Sex (Male/Female) 1 15/35 11/22 2/5 >.050
2 10/15 13/36 5/11 >.050
BMI (kg/m2) 1 25.59 ± 3.76 24.42 ± 3.94 27.27 ± 5.54 >.050
2 25.65 ± 3.24 25.30 ± 4.46 24.69 ± 3.76 >.050
Plasma renalase (μg/mL) 1 12.80 ± 4.54 13.46 ± 4.81 14.33 ± 2.54 >.050
2 11.88 ± 4.46 13.63 ± 4.60 13.73 ± 4.16 >.050
Continuous variables are presented as means ± SD (standard deviation). Discrete variables are presented as numbers. POL; polymorphism, 1-rs2576178,
2-rs10887800, BMI; Body Mass Index. *ANOVA or χ2 tests
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Table 3 Clinical characteristics of hemodialyzed patients classified according to the renalase gene polymorphisms
Variables POL Genotypes p value*
AA AG GG
Age (years) 1 64.33 ± 13.26 64.25 ± 14.97 61.69 ± 15.20 >.050
2 65.51 ± 15.07 63.94 ± 13.37 62.95 ± 14.51 >.050
Sex (Male/Female) 1 89/79 62/56 6/17 <.050
2 40/37 78/83 39/32 >.050
BMI (kg/m2) 1 25.50 ± 4.99 25.80 ± 4.64 27.53 ± 9.37 >.050
2 25.62 ± 4.62 25.45 ± 5.13 26.65 ± 6.31 >.050
Albumin (g/dL) 1 3.94 ± .39 3.93 ± .35 3.88 ± .48 >.050
2 3.95 ± .35 3.97 ± .38 3.84 ± .41 >.050
Hemoglobin (g/dL) 1 10.89 ± 1.49 10.90 ± 1.30 10.36 ± 1.22 >.050
2 10.91 ± 1.33 10.96 ± 1.43 10.56 ± 1.42 >.050
Dialysis time (years) 1 6.20 ± 6.46 6.27 ± 5.68 7.65 ± 8.13 >.050
2 5.50 ± 5.49 6.63 ± 6.24 6.59 ± 7.23 >.050
CHOL, n (%) 1 88 (52.38) 57 (48.30) 10 (43.47) >.050
2 39 (50.64) 83 (51.55) 33 (46.47) >.050
spKt/Vurea 1 1.38 ± .62 1.39 ± .51 1.36 ± .43 >.050
2 1.37 ± .60 1.37 ± .63 1.39 ± 35 >.050
RD, n (%) 1 67 (39.88) 48 (40.67) 14 (60.86) >.050
2 28 (36.36) 61 (37.88) 40 (56.33) <.050
Renalase (μg/mL) 1 33.31 ± 13.01 33.98 ± 11.22 33.09 ± 13.48 >.050
2 29.32a ± 9.89 34.52b ± 13.12 35.91b ± 12.07 <.010
Continuous variables are presented as means ± SD (standard deviation). Discrete variables are presented as numbers and percentages (in parentheses). POL;
polymorphism, 1-rs2576178, 2-rs10887800, BMI; Body Mass Index, CHOL; hypercholesterolemia, spKt/Vurea; single-pool Kt/V for urea, RD; residual diuresis.
*ANOVA or χ2 tests.
Fig. 1 Plasma renalase concentrations as a function of rs10887800 renalase gene polymorphism
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gene) and both glucose and triglyceride levels in a large
human population, thereby suggesting the association of this
SNP with cardiometabolic traits [15, 16]. Rezk et al. in a
study of 178 Egyptian patients with chronic kidney disease
(CKD) and 178 healthy controls have demonstrated a higher
level of norepinephrine among CKD patients with CC geno-
type of rs2296545 SNP (exon 2 of RNLS gene) compared to
GG and GC carriers. Similarly to our results, polymorphic
effect was not observed in healthy controls [17].
To date, only a few papers have shown RNLS SNP geno-
typing results in hemodialyzed populations. Kiseljakovic et
al. in a study of HD patients from Bosnia and Herzegovina
have reported higher G allele frequency of rs2576178
polymorphism compared to our results (0.44 vs 0.27), but
similar to the one observed by Ahlawat et al. in a CKD
population from North India (0.5) [18, 19]. The descre-
pancy between presented results could be attributed to
ethnic differences. Meanwhile, the prevalence of G allele
of rs10887800 SNP in our study was comparable to the
one in Chinese hypertensive population described by Zhao
et al. (0.49 vs 0.5) [7].
Our present study has revealed significantly higher level of
plasma RNLS in HD population compared to healthy con-
trols. Consistent results were obtained by other researchers
for patients undergoing both hemodialysis [20–23] and
peritoneal dialysis [24]. In all those studies RNLS level was
determined by commercially available ELISA kit (USCN Life
Science Inc., Wuhan, China) with monoclonal antibodies
specific to hRenalase1 isoform. Interestingly, the opposite
results were obtained by investigators using western blot
method with polyclonal antibodies [1, 13]. To clarify dis-
crepancy between results obtained by two different methods
it was assumed that ELISA-based assay preferentially detects
multimers of RNLS which are likely to be formed in ESKD.
Furthermore, increased RNLS concentration in advanced
CKD patients could be due to cross-reactivity with break-
down products of plasma RNLS, oversecretion of RNLS by
other tissues, i.e., cardiomyocytes, liver or skeletal muscles
in a presence of kidney failure, sympathetic hyperactivity
and decreased RNLS clearance [25].
Our recent studies of HD population have demonstrated
the association between RNLS gene polymorphisms and the
increased risk of cardiovascular diseases [8, 9], but the exact
mechanism underlying this link has remained unknown. On
the basis of current findings we presume that rs10887800
polymorphism of RNLS gene can modify the risk of different
human diseases due to modulation of plasma RNLS level.
However, since the mechanism of RNLS action is still largely
undefined, the extended interpretation of our results should
be cautious. Furthermore, previously published data on the
pathophysiological role of RNLS have provided contrary
results. For instance, in our recent paper rs10887800GG
genotype (e.i., related to the higher level of RNLS) was
shown to increase the risk of CAD [9], whereas in a study of
He et al. plasma RNLS concentration has reversly correleted
with the CAD severity [26].
Some limitations should be considered in the interpret-
ation of our findings. Firstly, the study population involved
only Caucasian individuals. Therefore, the results may not
be generalized to other ethnic groups. Secondly, we did
not assess the level of RNLS in urine and dialysis fluid,
which could clarify obtained results. Furthermore, the
plasma RNLS activity and its intracellular expression were
not evaluated. In addition, RNLS measurement method
used by us needs further improvements, particularly in
the area of better standarization in a population with
ESKD. Finally, the in-depth analyses of the impact of
rs10887800 polymorphism on RNLS level in subgroups of
patients with particular human diseases are needed. How-
ever, this is a subject of our ongoing studies.
Conclusion
The present study suggests for the first time that
rs10887800 polymorphism of the RNLS gene influences the
level of circulating RNLS and thus elucidates its functional
relevance in hemodialyzed population. Even though many
questions remain open, obtained results provide an import-
ant insight into probable mechanisms by which RNLS gene
variants affect the risk of human diseases. Further investiga-
tions on a larger size sample and other ethnic groups are
neccesary to confirm and elaborate on our novel findings.
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